Noopept

also known as: GVS-111, Omberacetam, N-phenylacetyl-L-prolylglycine ethyl ester

A Russian-developed prolyl-glycine-ester nootropic — often grouped with racetams despite being a dipeptide, with BDNF/NGF upregulation and anxiolytic activity.

A dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in the 1990s, included in peptide compendia by convention; metabolized to cycloprolylglycine, the endogenous form of which has nootropic activity.

Mechanism of action

Metabolized to cycloprolylglycine (CPG), which upregulates BDNF and NGF expression in the hippocampus and cortex. Additional actions include modulation of AMPA and NMDA receptor function, inhibition of glutamate excitotoxicity, and anxiolytic effects mediated through the cholinergic system. In-vivo potency is approximately 1000× that of piracetam by weight.

Primary uses

Cognitive impairment (Russian approval)
Mild cognitive impairment research
Community nootropic use

Typical dosing

10–30 mg 2–3 times daily (oral or sublingual)

Russian clinical dose: 10 mg twice daily, titrated to 30 mg/day if needed.

Regulatory status

Approved in Russia for cognitive impairment associated with organic brain disorders. Not approved by the FDA.

References

[pubmed] Ostrovskaya RU, et al. "The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model." J Psychopharmacol, 2007;21:611-619.
[pubmed] Neznamov GG, Teleshova ES. "Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin." Neurosci Behav Physiol, 2009;39:311-321.

Related peptides

Semax

A synthetic ACTH-derived heptapeptide approved in Russia for stroke rehabilitation and optic nerve disorders, with documented BDNF upregulation and broad nootropic activity.

Selank

A Russian-developed tuftsin analog approved for anxiety — produces benzodiazepine-like anxiolysis via GABAergic modulation without sedation, dependence, or withdrawal.

Cerebrolysin

A porcine-derived neurotrophic peptide preparation approved in 40+ countries (not US) for stroke, dementia, and traumatic brain injury — with the largest clinical evidence base of any nootropic peptide preparation.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.